Targeting oncogenic pathways has led to recent exciting advances in multiple cancers, including vemurafenib in BRAF mutant melanoma, erlotinib in EGFR mutant non-small cell lung cancer, and crizotinib in lung cancer with the EMLA4-ALK translocation [16]–[18]. This evidence concerns the gene BRAF and cancer.